Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Analog Devices
ADI
|
+$384M |
| 2 |
VMW
VMware, Inc
VMW
|
+$286M |
| 3 |
UnitedHealth
UNH
|
+$192M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$158M |
| 5 |
IQVIA
IQV
|
+$132M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SJR
Shaw Communications Inc.
SJR
|
+$473M |
| 2 |
Dynatrace
DT
|
+$329M |
| 3 |
Salesforce
CRM
|
+$318M |
| 4 |
Microsoft
MSFT
|
+$253M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$191M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.32% |
| 2 | Technology | 16.45% |
| 3 | Financials | 12.17% |
| 4 | Industrials | 7.23% |
| 5 | Communication Services | 3.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Blackstone
BX
$108B
| $284M | 1.43% |
3,058,251
-81,700
| -3% | -$7.06M |
|
27
ServiceNow
NOW
$133B
| $279M | 1.4% |
2,485,250
-1,013,000
| -29% | -$101M |
|
28
Boston Scientific
BSX
$73B
| $273M | 1.37% |
5,045,257
-2,660,000
| -35% | -$139M |
|
29
Equifax
EFX
$22.6B
| $249M | 1.25% |
1,058,697
-337,900
| -24% | -$71.1M |
|
30
Visa
V
$693B
| $247M | 1.24% |
1,039,310
+29,900
| +3% | +$6.84M |
|
31
CoStar Group
CSGP
$13.1B
| $245M | 1.23% |
2,751,056
-660,129
| -19% | -$51M |
|
|
XYZ
32
Block Inc
XYZ
$49.4B
| $223M | 1.12% |
3,344,050
+483,000
| +17% | +$30.2M |
|
33
Elevance Health
ELV
$86.9B
| $198M | 0.99% |
445,330
-228,300
| -34% | -$105M |
|
34
Biogen
BIIB
$32B
| $172M | 0.86% |
604,098
-15,700
| -3% | -$4.67M |
|
35
Alibaba
BABA
$286B
| $156M | 0.78% |
1,870,000
+70,000
| +4% | +$6.13M |
|
36
Sarepta Therapeutics
SRPT
$1.98B
| $138M | 0.69% |
1,205,200
+291,900
| +32% | +$37.6M |
|
|
SGEN
37
DELISTED
Seagen Inc. Common Stock
SGEN
| $135M | 0.68% |
700,000
+475,000
| +211% | +$94.4M |
|
|
SYNH
38
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $130M | 0.65% |
3,075,000
+2,603,000
| +551% | +$105M |
|
39
Protagonist Therapeutics
PTGX
$9.99B
| $125M | 0.63% |
4,511,430
+1,896,416
| +73% | +$47.5M |
|
40
Humana
HUM
$45.5B
| $116M | 0.58% |
258,461
+13,800
| +6% | +$6.95M |
|
41
Lantheus
LNTH
$6.53B
| $114M | 0.57% |
1,360,500
+1,176,500
| +639% | +$106M |
|
42
Pacific Biosciences
PACB
$420M
| $111M | 0.56% |
8,338,120
+1,983,000
| +31% | +$24.1M |
|
43
Beam Therapeutics
BEAM
$3.07B
| $110M | 0.55% |
3,441,522
+9,601
| +0.3% | +$312K |
|
44
Inspire Medical Systems
INSP
$1.8B
| $105M | 0.53% |
323,096
+80,500
| +33% | +$23M |
|
|
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $96.1M | 0.48% |
2,442,299
+1,957,500
| +404% | +$69.1M |
|
46
PG&E
PCG
$38.8B
| $86.5M | 0.43% |
5,005,142
| – | – |
|
47
HCA Healthcare
HCA
$92.9B
| $79.6M | 0.4% |
262,400
+105,800
| +68% | +$29.4M |
|
48
Agios Pharmaceuticals
AGIO
$1.98B
| $76.1M | 0.38% |
2,688,829
+596,000
| +28% | +$14.8M |
|
49
Revolution Medicines
RVMD
$44.9B
| $74.5M | 0.37% |
2,783,480
-500,120
| -15% | -$12.3M |
|
50
KE Holdings
BEKE
$19.6B
| $70.7M | 0.35% |
4,758,500
| – | – |
|
Similar funds
Thomas Steyer's Q2 2023 Portfolio in Review
As of Q2 2023, Thomas Steyer held 208 positions worth $19.9B, up 8.8% from $18.3B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Thomas Steyer's Q2 2023 filing shows 17 new, 41 increased, 35 reduced and 35 closed positions. Its largest new stake was Analog Devices: 2,075,000 shares worth $404M. The largest sale was Shaw Communications Inc., an estimated $473M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Financials.
- Thomas Steyer's largest Q2 2023 buy was Analog Devices: 2,075,000 shares worth $404M.
- Thomas Steyer added most to VMware, Inc in Q2 2023, an estimated $286M increase.
- Thomas Steyer's biggest Q2 2023 reduction was Salesforce, cutting an estimated $318M.
- Thomas Steyer fully exited Shaw Communications Inc. in Q2 2023, selling an estimated $473M.
- Thomas Steyer's ten largest holdings make up 44% of its $19.9B portfolio in Q2 2023.
- Thomas Steyer opened 17 new positions and closed 35 in Q2 2023.
- Thomas Steyer's portfolio value rose 8.8% quarter-over-quarter to $19.9B.
Based on Farallon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.